EGFR and non-small cell lung carcinoma: In an ongoing phase I clinical trial at Sun Yat-Sen University, CXCR-5-modified anti-EGFR CAR-T cells are being used to treat patients with NSCLC and are being evaluated for efficacy and safety (NCT04153799).